Hims & Hers Health has closed its acquisition of Eucalyptus, adding an Australia-founded digital health platform with operations spanning Australia, Canada, Germany, Japan, and the UK. Terms were not disclosed. The purchase extends a cross-border roll-up strategy that already included ZAVA and Livewell, and it gives Hims & Hers a broader clinical and regulatory footprint outside the US.
Eucalyptus says it has served more than 850,000 customers as of May 2026. For Hims & Hers, that matters less as a headline customer count than as a shortcut through the slow work of localization. Consumer health platforms do not scale internationally by simply translating an app. They need prescribing workflows, pharmacy relationships, clinician networks, advertising compliance, and data handling practices tailored to each jurisdiction. Eucalyptus brings that operating infrastructure.
The acquisition also sharpens Hims & Hers' underlying business model. The company has spent years proving that direct-to-consumer telehealth can acquire patients efficiently in categories such as weight loss, sexual health, dermatology, and mental health. The harder question is whether those economics hold as competition rises and regulators scrutinize online prescribing. International expansion offers a new answer. A larger geographic base diversifies regulatory risk, widens the pool of reimbursed and cash-pay opportunities, and creates more leverage for product launches with pharmaceutical partners.
That helps explain the company’s emphasis on a “closed-loop ecosystem” and long-term targets of $6.5 billion in revenue and $1.3 billion in adjusted EBITDA by 2030. Scale is not just a branding exercise here. It is a bid for lower customer acquisition costs, better retention, and more negotiating power across pharmacy, fulfillment, and clinical operations.
The timing fits a market that is rewarding larger, more defensible healthcare platforms. Acquire.fyi data shows health sector deal value has reached $75.5 billion year to date, up 88.7%, even as volume has fallen 7.8%. Buyers are doing fewer deals, but they are paying up for assets that solve distribution, compliance, or margin pressure in one move.
Execution risk now shifts to integration. Hims & Hers has assembled an international patchwork. The next test is whether it can make those assets operate like one platform before regulators, local incumbents, or rising customer acquisition costs erode the benefits of scale.
Source: Company press release and Acquire.fyi's proprietary data
